HC Wainwright Reaffirms Neutral Rating for BioAtla (NASDAQ:BCAB)

BioAtla (NASDAQ:BCAB)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports.

BioAtla Stock Performance

NASDAQ:BCAB opened at $0.35 on Monday. The stock has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $1.10. BioAtla has a 52-week low of $0.24 and a 52-week high of $4.02. The company has a market cap of $17.08 million, a PE ratio of -0.21 and a beta of 1.19.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. On average, research analysts predict that BioAtla will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAtla

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Magnus Financial Group LLC acquired a new stake in shares of BioAtla in the fourth quarter valued at about $28,000. Two Sigma Investments LP grew its stake in BioAtla by 84.0% in the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after purchasing an additional 61,725 shares in the last quarter. Jane Street Group LLC increased its position in shares of BioAtla by 204.1% during the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after purchasing an additional 100,204 shares during the last quarter. XTX Topco Ltd raised its stake in shares of BioAtla by 7.2% during the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after purchasing an additional 10,384 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of BioAtla during the 4th quarter worth approximately $230,000. 77.23% of the stock is owned by institutional investors.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.